Skip to main content
SpringerLink
Log in

Evaluation of EGFR, KRAS, and TP53 mutations as predictive of disease recurrence in resected early non-small cell lung carcinomas (NSCLCs)

  • original report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Identification of non-small cell lung carcinoma (NSCLC) patients at high-risk for recurrence after complete resection would potentially direct surveillance frequency and administration of adjuvant treatments. Genetic profiling of tumors could provide clinicians with information regarding recurrence risk. Conflicting evidence exists regarding EGFR, KRAS, and TP53 mutations as prognostic for recurrence. We aimed to test such mutations for prognostic significance in a cohort of early-resected NSCLC specimens.

Materials and methods

Formalin-fixed paraffin-embedded stage I NSCLC specimens resected in our institute during 1988–2008 were sampled. DNA was extracted and a panel of common EGFR, KRAS, and TP53 mutations was tested using a mass-spectrometry-based technique. Clinical data were extracted from patients’ files.

Results

A total of 96 NSCLC stage I patients were included in this study. EGFR mutation frequency of 15.6 %, KRAS mutation frequency of 15.6 %, and a TP53 mutation frequency of 6.2 % were found. A nonsignificant trend for longer relapse-free survival (RFS) was seen for patients with an EGFR mutation, and a nonsignificant trend for worse RFS was found for patients with a KRAS mutation.

Conclusion

EGFR mutation and KRAS mutation were not found to be prognostic for RFS in our cohort of early NSCLC. Larger cohorts and a broader genetic screen for mutations are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69–90.

  2. Tambo Y, Kasahara K, Sone T, Kimura H, Sakai A, Araya T, et al.  Prognostic and predictive impact of EGFR and K-ras mutation, and EGFR gene copy number in patients with advanced non-small cell lung cancer (NSCLC) who received first-line cytotoxic chemotherapy. J Clin Oncol. 2009;27:15 S. Abstract no. 8096.

    Google Scholar 

  3. D’Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012 Dec;7(12):1815–22.

    Article  PubMed  CAS  Google Scholar 

  4. Chau NG, Perez-Ordonez B, Zhang K, Pham NA, Ho J, Zhang T, et al. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol. 2011;3:11.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  5. Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2009 Jan;4(1):22–9.

    Article  PubMed  Google Scholar 

  6. Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008 Feb;3(2):111–6.

    Article  PubMed  Google Scholar 

  7. Koga T, Takeshita M, Yano T, Maehara Y, Sueishi K. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. Int J Cancer. 2011 Mar 1;128(5):1009–17.

  8. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990 Aug 30;323(9):561–5.

  9. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005 Jan 17;92(1):131–9.

  10. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small cell lung cancer. J Clin Oncol. 2007 Nov 20;25(33):5240–7.

  11. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res. 2000 Oct;6(10):4055–63.

    PubMed  CAS  Google Scholar 

  12. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001 Oct;18(4):705–19.

    Article  PubMed  CAS  Google Scholar 

  13. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar;39(3):347–51.

    Article  PubMed  CAS  Google Scholar 

  14. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005 Apr;40(2):90–7.

    Article  PubMed  Google Scholar 

  15. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009 Sep 3;361(10):958–67.

  16. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239–46.

    Article  PubMed  CAS  Google Scholar 

  17. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005 Sep 1;23(25):5900–9.

  18. Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013 Mar 10;31(8):1070–80.

  19. Shepherd FA, Domerg C, Hainaut P, Janne PA, Pignon JP, Graziano S, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol. 2013 Jun 10;31(17):2173–81.

  20. Martin P, Leighl NB, Tsao MS, Shepherd FA. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol. 2013 May;8(5):530–42.

    PubMed  CAS  Google Scholar 

  21. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000 Dec 1;60(23):6750–6.

  22. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001 Dec;1(3):233–40.

    Article  PubMed  CAS  Google Scholar 

Download references

Take home message

Examination of early-resected NSCLC specimens for the presence of mutations in the EGFR, KRAS, and TP53 genes is feasible. The prognostic value of such mutations is not clear in early NSCLC.

Acknowledgments

This study was supported by a Flight Attendant Medical Research Institute grant.

The funding source had no role in the conduct of the study, in the writing of the manuscript, or its approval.

Conflict of interest

All authors declare that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Institute of Oncology, Sheba Medical Center, 5262000, Tel-Hashomer, Ramat Gan, Israel

    Jair Bar MD, PhD & Amir Onn MD

  2. Cancer Research Center, Sheba Medical Center, 5262000, Tel-Hashomer, Ramat Gan, Israel

    Jair Bar MD, PhD, Maya Damianovich MD, Goni Hout Siloni MSc, Erel Dar BMedSc, Yehudit Cohen PhD, Yoram Cohen MD, Ronit I Yarden PhD & Amir Onn MD

  3. Institute of Pathology, Sheba Medical Center, 5262000, Tel-Hashomer, Ramat Gan, Israel

    Oranit Zadok, Marina Perelman MD & Iris Barshack MD

  4. Department of Human Science, SNHS, the Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA

    Ronit I Yarden PhD

  5. Thoracic Surgery, Sheba Medical Center, 5262000, Tel-Hashomer, Ramat Gan, Israel

    David Simansky MD & Alon Ben Nun MD, PhD

Authors
  1. Jair Bar MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maya Damianovich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Goni Hout Siloni MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Erel Dar BMedSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yehudit Cohen PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Oranit Zadok
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoram Cohen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marina Perelman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Iris Barshack MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ronit I Yarden PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. David Simansky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Alon Ben Nun MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Amir Onn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jair Bar MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bar, J., Damianovich, M., Siloni, G. et al. Evaluation of EGFR, KRAS, and TP53 mutations as predictive of disease recurrence in resected early non-small cell lung carcinomas (NSCLCs). memo 7, 10–15 (2014). https://doi.org/10.1007/s12254-014-0132-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-014-0132-1

Keywords

Search

Navigation